Hiprex 1g tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hiprex 1g tablets

de pharmaceuticals - methenamine hippurate - oral tablet - 1gram

HIP REX TAB 1GM TABLET Canada - English - Health Canada

hip rex tab 1gm tablet

graceway pharmaceuticals - methenamine hippurate - tablet - 1g - methenamine hippurate 1g - urinary anti-infectives

UROAV-B- methenamine, sodium phosphate, monobasic, anhydrous, phenyl salicylate, methylene blue and hyoscyamine sulfate capsule United States - English - NLM (National Library of Medicine)

uroav-b- methenamine, sodium phosphate, monobasic, anhydrous, phenyl salicylate, methylene blue and hyoscyamine sulfate capsule

avkare - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, anhydrous (unii: kh7i04hpuu) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 118 mg - uroav-b capsules are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uroav-b capsules are contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).

URO-MP- methenamine, sodium phosphate, monobasic, anhydrous, phenyl salicylate, methylene blue and hyoscyamine sulfate capsule United States - English - NLM (National Library of Medicine)

uro-mp- methenamine, sodium phosphate, monobasic, anhydrous, phenyl salicylate, methylene blue and hyoscyamine sulfate capsule

method pharmaceuticals, llc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, anhydrous (unii: kh7i04hpuu) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 118 mg - uro-mp capsules are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uro-mp capsules are contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).

URAMIT MB methenamine sodium phosphate monobasic monohydrate phenyl salicylate methylene blue and hyoscyamine sulfate capsule United States - English - NLM (National Library of Medicine)

uramit mb methenamine sodium phosphate monobasic monohydrate phenyl salicylate methylene blue and hyoscyamine sulfate capsule

burel pharmaceuticals, inc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv) - methenamine 118 mg

CVS ANTIBACTERIAL PLUS URINARY PAIN RELIEF- methenamine, sodium salicylate tablet United States - English - NLM (National Library of Medicine)

cvs antibacterial plus urinary pain relief- methenamine, sodium salicylate tablet

cvs pharmacy, inc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium salicylate (unii: wiq1h85syp) (salicylic acid - unii:o414pz4lpz) - methenamine 162 mg - antibacterial analgesic (pain reliever) uses temporarily relieves: pain & burning • frequency and urgency of urination

URIN D/S- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate tabl United States - English - NLM (National Library of Medicine)

urin d/s- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate tabl

llorens pharmaceutical international division - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 81.6 mg - indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of urin d/s has not been reported and due to the nature of its ingredients, abuse of urin d/s is not expected.

UROGESIC BLUE methenamine sodium phosphate monobasic methylene and hyoscyamine sulfate tablet United States - English - NLM (National Library of Medicine)

urogesic blue methenamine sodium phosphate monobasic methylene and hyoscyamine sulfate tablet

edwards pharmaceutical, inc. - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv) - methenamine 81.6 mg

UROGESIC BLUE- methenamine, sodium phosphate, monobasic, methylene blue, and hyoscyamine sulfate tablet, coated United States - English - NLM (National Library of Medicine)

urogesic blue- methenamine, sodium phosphate, monobasic, methylene blue, and hyoscyamine sulfate tablet, coated

edwards pharmaceuticals, inc. - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic (unii: 3980jih2sw) (sodium cation - unii:lyr4m0nh37), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 81.6 mg - urogesic-blue™ is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as hypermotility which accompany lower urinary tract infections and as antispasmodic. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. urogesic-blue™ is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrythmias, congestive heart failure, coronary heart disease, mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of urogesic-blue™ has not been reported and due to the nature of its ingredients, abuse of urogesic-blue™ is not expected.

USTELL- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate capsul United States - English - NLM (National Library of Medicine)

ustell- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate capsul

star pharmaceuticals llc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 120 mg - ustell™ capsules are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of ustell™ capsules has not been reported and due to the nature of its ingredients, abuse of ustell™ capsules is not expected.